AusBiotech positive about working with Julia Gillard
07 July, 2010 by David BinningPeak industry body AusBiotech said today that it was confident of working with new prime minister Julia Gillard to develop a more effective legislative framework for the Australian biotechnology industry.
AtCor adds to run of sales since March
07 July, 2010 by David BinningAtCor Medical announced today that it has signed a US$1.77 million contract for the supply of its SphygmoCor blood pressure measurement system to a U.S customer.
Avexa axes board
06 July, 2010 by David BinningShareholders in Avexa today voted resoundingly in favour of ousting existing chairman and director Nathan Drona along with the company’s entire board.
Patrys granted U.S patent for lead human anti-body product
06 July, 2010 by David BinningPatrys announced today that it has received a U.S patent for its lead product PATPM1, a promising new human antibody shown to be effective in the treatment of solid tumors and metastases across a number of indicators including pancreatic, lung, breast, colon and gastric cancers.
Market Report: fears of double dip U.S recession continue to haunt
02 July, 2010 by David BinningAustralian shares staged a small comeback on Friday ending eight days of consecutive losses incured as investors eyed the looming spectre of a double-dip recession in the U.S, while data out of China showed that measures aimed at slowing its economy were working.
Clinuvel awarded U.S patent for use of Scenesse in UV protection
02 July, 2010 by Staff WritersMelbourne-based Clinuvel has received a U.S patent acknowledging the role of so-called melanocortin drugs in providing UV protection for fair skinned people who have a genetic variation in the melanocortin-1 receptor (MC1R).
Abbott rumoured to be selling flu vaccine business
02 July, 2010 by David BinningAbbott Laboratories is believed to be considering the sale of its flu business, gained earlier in the year through its acquisition of Belgium’s Solvay Pharmaceuticals.
Novartis to outperform wider pharma industry
01 July, 2010 by David BinningSwiss-based Novartis is expected to be the world’s best performing pharmaceutical company over the next five years, bolstered by its vaccine and generics businesses.
Roundtable: from innovation to commercialisation - Part II: the valley of death
29 June, 2010 by Tim DeanIn this section of the roundtable the panellists discussed the so-called 'valley of death' between a promising discovery and having a product that the industry will actually put money behind.
Amgen ready to go shopping
28 June, 2010 by David BinningGlobal biotech company Amgen has acknowledged that proposed changes to the R&D tax credit arrangements would increase the appeal of the Australian biotech industry as the company prepares to embark on a global spending spree.
Roundtable: from innovation to commercialisation - Part I: research and business
28 June, 2010 by Tim DeanIt's the perennial question: how do we effectively translate cutting edge research into successful products in the market? Australian Life Scientist brought together a panel of industry luminaries to discuss the challenges of commercialisation in Australia.
Market report: Jitters return following poor U.S economic data
25 June, 2010 by David BinningAustralian shares slumped to a fortnightly low on Friday, weighed down by concerns about the U.S and Europe as well as uncertainty surrounding the proposed resources super profits tax (RSPT).
ImpediMed clears final U.S hurdle for biompedance product
25 June, 2010 by David BinningBrisbane biotech ImpediMed announced today that it has received a Category III coding from the American Medical Association ( AMA ) for the use of its L-Dex U400 bioimpedance spectroscopy ( BIS ) technology in the detection of lymphoedema in limbs, which will take effect on January 1 next year.
First cannabis-based drug approved in Europe
25 June, 2010 by David BinningThe first cannabis-based pharmaceutical product has been approved in the UK, paving the way for widespread adoption throughout Europe.
Market Report: Cautious end to upbeat week
18 June, 2010 by David BinningThe Australian stock market finished the week up one percent, although thin trade volumes today suggested that investors were exercising caution amid ongoing global uncertainty.
